Aclarion shares surged over 45% premarket after the company reported strong momentum for its Nociscan platform. Annual scan volumes rose 69% in 2025, with triple-digit growth in Q4, as new imaging sites and physicians joined. Aclarion plans to accelerate clinical trial enrollment and launch upgraded software in 2026.